Trial Profile
Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Dapaconazole (Primary) ; Ketoconazole
- Indications Tinea pedis
- Focus Registrational; Therapeutic Use
- Sponsors Biolab Sanus Farmaceutica
- 24 Jul 2020 Status changed from recruiting to completed.
- 15 Jan 2019 Planned End Date changed from 1 Feb 2019 to 1 Nov 2019.
- 15 Jan 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2019.